Gourmia's New PanoramaTM Next-Gen Digital Air Fryer with Internal Hologram at Walmart
The Christmas tradition has become nearly global in scope: Children from around the world track Santa Claus as he sweeps across the earth, delivering presents and defying time. Each year, at least 100,000 kids call into the North American Aerospace Defense Command to inquire about Santa’s location. Millions more follow online in nine languages , from English to Japanese. On any other night, NORAD is scanning the heavens for potential threats , such as last year’s Chinese spy balloon . But on Christmas Eve, volunteers in Colorado Springs are fielding questions like, “When is Santa coming to my house?” and, “Am I on the naughty or nice list?” “There are screams and giggles and laughter,” said Bob Sommers, 63, a civilian contractor and NORAD volunteer. Sommers often says on the call that everyone must be asleep before Santa arrives, prompting parents to say, “Do you hear what he said? We got to go to bed early.” NORAD’s annual tracking of Santa has endured since the Cold War , predating ugly sweater parties and Mariah Carey classics . Here’s how it began and why the phones keep ringing. The origin story is Hollywood-esque It started with a child’s accidental phone call in 1955. The Colorado Springs newspaper printed a Sears advertisement that encouraged children to call Santa, listing a phone number. A boy called. But he reached the Continental Air Defense Command, now NORAD, a joint U.S. and Canadian effort to spot potential enemy attacks. Tensions were growing with the Soviet Union, along with anxieties about nuclear war. Air Force Col. Harry W. Shoup picked up an emergency-only “red phone” and was greeted by a tiny voice that began to recite a Christmas wish list. “He went on a little bit, and he takes a breath, then says, ‘Hey, you’re not Santa,’” Shoup told The Associated Press in 1999. Realizing an explanation would be lost on the youngster, Shoup summoned a deep, jolly voice and replied, “Ho, ho, ho! Yes, I am Santa Claus. Have you been a good boy?” Shoup said he learned from the boy’s mother that Sears mistakenly printed the top-secret number. He hung up, but the phone soon rang again with a young girl reciting her Christmas list. Fifty calls a day followed, he said. In the pre-digital age, the agency used a 60-by-80 foot (18-by-24 meter) plexiglass map of North America to track unidentified objects. A staff member jokingly drew Santa and his sleigh over the North Pole. The tradition was born. “Note to the kiddies,” began an AP story from Colorado Springs on Dec. 23, 1955. “Santa Claus Friday was assured safe passage into the United States by the Continental Air Defense Command.” In a likely reference to the Soviets, the article noted that Santa was guarded against possible attack from “those who do not believe in Christmas.” Is the origin story humbug? Some grinchy journalists have nitpicked Shoup’s story, questioning whether a misprint or a misdial prompted the boy’s call. In 2014, tech news site Gizmodo cited an International News Service story from Dec. 1, 1955, about a child’s call to Shoup. Published in the Pasadena Independent, the article said the child reversed two digits in the Sears number. “When a childish voice asked COC commander Col. Harry Shoup, if there was a Santa Claus at the North Pole, he answered much more roughly than he should — considering the season: ‘There may be a guy called Santa Claus at the North Pole, but he’s not the one I worry about coming from that direction,’” Shoup said in the brief piece. In 2015, The Atlantic magazine doubted the flood of calls to the secret line, while noting that Shoup had a flair for public relations. Phone calls aside, Shoup was indeed media savvy. In 1986, he told the Scripps Howard News Service that he recognized an opportunity when a staff member drew Santa on the glass map in 1955. A lieutenant colonel promised to have it erased. But Shoup said, “You leave it right there,” and summoned public affairs. Shoup wanted to boost morale for the troops and public alike. “Why, it made the military look good — like we’re not all a bunch of snobs who don’t care about Santa Claus,” he said. Shoup died in 2009. His children told the StoryCorps podcast in 2014 that it was a misprinted Sears ad that prompted the phone calls. “And later in life he got letters from all over the world,” said Terri Van Keuren, a daughter. “People saying ‘Thank you, Colonel, for having, you know, this sense of humor.’” A rare addition to Santa’s story NORAD’s tradition is one of the few modern additions to the centuries-old Santa story that have endured, according to Gerry Bowler, a Canadian historian who spoke to the AP in 2010. Ad campaigns or movies try to “kidnap” Santa for commercial purposes, said Bowler, who wrote “Santa Claus: A Biography.” NORAD, by contrast, takes an essential element of Santa’s story and views it through a technological lens. In a recent interview with the AP, Air Force Lt. Gen. Case Cunningham explained that NORAD radars in Alaska and Canada — known as the northern warning system — are the first to detect Santa. He leaves the North Pole and typically heads for the international dateline in the Pacific Ocean. From there he moves west, following the night. “That’s when the satellite systems we use to track and identify targets of interest every single day start to kick in,” Cunningham said. “A probably little-known fact is that Rudolph’s nose that glows red emanates a lot of heat. And so those satellites track (Santa) through that heat source.” NORAD has an app and website, www.noradsanta.org , that will track Santa on Christmas Eve from 4 a.m. to midnight, Mountain Standard Time. People can call 1-877-HI-NORAD to ask live operators about Santa’s location from 6 a.m. to midnight, mountain time.How to Maintain The HHB Electric Chain Hoist for Longevity 12-20-2024 06:44 PM CET | Associations & Organizations Press release from: ABNewswire An HHB electric chain hoist [ https://www.sharehoist.com/hhb-electric-chain-hoist-product/ ] is a valuable asset in many industries, providing reliable lifting solutions. To ensure its longevity and optimal performance, regular maintenance is crucial. This article will guide you through essential maintenance tips to keep your HHB hoist in top condition. Why Regular Maintenance is Important Regular maintenance not only extends the lifespan of your HHB hoist but also: - Ensures safety: Regular inspections and maintenance can identify potential safety hazards before they become serious issues. - Improves efficiency: A well-maintained hoist operates more smoothly and efficiently, reducing downtime. - Protects your investment: Proper maintenance can help prevent costly repairs or replacements. Essential Maintenance Tips 1. Regular Inspections: - Visual inspection: Check for any visible signs of wear, damage, or corrosion on the hoist, chains, and hooks. - Functional test: Regularly lift a test load to ensure the hoist operates smoothly and safely. - Lubrication: Check lubrication points and reapply lubricant as needed to prevent wear and corrosion. 2. Chain Inspection and Maintenance: - Wear and damage: Inspect the chain for any signs of wear, stretch, or damage. Replace any damaged links or sections. - Lubrication: Regularly lubricate the chain to reduce friction and wear. - Alignment: Ensure the chain is properly aligned to prevent binding and uneven wear. 3. Motor and Electrical Components: - Overheating: Check for signs of overheating, such as excessive heat or burning smells. - Electrical connections: Inspect all electrical connections for loose wires or damage. - Control panel: Clean the control panel and ensure all buttons and switches operate smoothly. 4. Brake System: - Adjustment: Regularly adjust the brake system to ensure it engages properly and holds the load securely. - Wear: Inspect the brake linings for wear and replace them as needed. 5. Limit Switches: - Function: Test the upper and lower limit switches to ensure they operate correctly and prevent the hoist from over-traveling. - Adjustment: Adjust the limit switches as needed to match the specific lifting requirements. 6. Hook Inspection: - Wear and damage: Inspect the hook for cracks, deformation, or other signs of damage. - Latch: Ensure the hook latch is secure and operates smoothly. 7. Cleaning: - Regular cleaning: Keep the hoist clean by removing dirt, debris, and oil. - Avoid harsh chemicals: Use mild cleaning agents to avoid damaging the hoist's components. Creating a Maintenance Schedule To ensure that your HHB electric chain hoist receives the necessary maintenance, it is advisable to create a regular maintenance schedule. Consider factors such as the frequency of use, working environment, and manufacturer's recommendations. Safety Precautions - Authorized personnel: Only trained and authorized personnel should perform maintenance on the hoist. - Lockout/tagout: Always follow lockout/tagout procedures before performing any maintenance. - Follow manufacturer's instructions: Refer to the manufacturer's manual for specific maintenance guidelines. Conclusion By following these maintenance tips, you can significantly extend the lifespan of your HHB electric chain hoist and ensure its safe and reliable operation. Regular inspections and maintenance are essential for preventing unexpected breakdowns and minimizing downtime. Remember, a well-maintained hoist is a valuable asset that will serve you for many years to come. For more insights and expert advice, visit our website at https://www.sharehoist.com/ to learn more about our products and solutions. Media Contact Company Name: Hebei XiongAn Share Technology Co., Ltd. i Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=how-to-maintain-your-hhb-electric-chain-hoist-for-longevity ] Country: China Website: https://www.sharehoist.com/ This release was published on openPR.
NoneREDWOOD SHORES, Calif.--(BUSINESS WIRE)--Dec 20, 2024-- Reltio ®, a leader in data unification and management, announced it has been recognized in the recently released Gartner Market Guide for Master Data Management Solutions report. The Gartner report examines the evolving MDM market and is designed as a guide for companies seeking an MDM solution. Reltio Data CloudTM encompasses Reltio’s entire ecosystem of solutions, including Reltio Customer 360TM, Multidomain Master Data Management (MDM), and Entity Resolution, and is classified in the report as a best-of-breed solution. The report notes, “Reltio’s vision is one of convergence of active metadata, data quality and MDM into a unified data management stack facilitating the collection, unification, activation and governance of data aligned with architecture patterns like data fabric.” In discussing Reltio’s AI offerings and security, the report states, “AI productivity enhancements include rule-free entity resolution and anomaly detection; conversational data exploration; and segmentation via Reltio Intelligent Assistant (RIA). In addition to SSO and client credentials, Reltio supports native multifactor authentication.” “Data-driven business strategies—including the rising tide of AI projects—are increasingly complex. Companies now have unique demands for AI-fueled capabilities for data management, and solutions that adhere to strict compliance standards. They also need increased cybersecurity features, as well as continuous progress toward true data unification,” said Manish Sood, CEO, Founder, and Chairman of Reltio. “The Reltio Data Cloud makes that all possible by updating data in real-time while also ensuring compliance, improving security, and providing business teams and users with the data they need from anywhere across the organization, when they need it.” The complete Gartner MDM Market Guide, authored by Gartner analysts Helen Grimster, Sally Parker, Gavin Hicks and Stephen Kennedy is available on Reltio. Reltio proudly serves companies of all sizes, including 13 of the Fortune 100 and globally recognized customers such as Pfizer, CarMax, Radisson Hotel Group, Warner Bros Discover, Shiseido, and Schneider Electric. Gartner, Market Guide for Master Data Management Solutions, Helen Grimster, Sally Parker, Gavin Hicks and Stephen Kennedy, December 17, 2024 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About Reltio At Reltio, we believe data should accelerate the speed of business and fuel your success. Our AI-powered data unification and management offerings deliver unified, trusted data where and when it's needed, so that enterprises can be responsive to changing business needs. Reltio Data CloudTM (formerly “Reltio Connected DataTM Platform”) encompasses our entire ecosystem of solutions, including Reltio Customer 360TM, Multidomain Master Data Management (MDM), and Entity Resolution. Reltio Data Cloud unifies disparate data sources in real-time, creating a single, trusted source of truth. Leading enterprise brands across multiple industries around the globe rely on our award-winning data unification and management capabilities to improve efficiency, manage risk, and drive growth. “Reltio” is a registered trademark, and “Reltio Customer 360”, “Reltio Data Cloud”, and “Reltio Connected Data Platform” are trademarks of, Reltio, Inc. All Rights Reserved. View source version on businesswire.com : https://www.businesswire.com/news/home/20241220365263/en/ CONTACT: Alan Ryan Allison Worldwide for Reltio Reltio@allisonworldwide.com KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SOFTWARE TECHNOLOGY DATA MANAGEMENT SOURCE: Reltio Copyright Business Wire 2024. PUB: 12/20/2024 12:23 PM/DISC: 12/20/2024 12:23 PM http://www.businesswire.com/news/home/20241220365263/en
Opinion | Scott M. Estill: Dillon recall petitions should be withdrawn
Lululemon just dropped the cutest plush wristlet — it's under $60, and it would make a great gift idea
Trump's Middle East envoy travelled to Israel, Qatar for Gaza ceasefire talks: ReportNone
Why Is Ulta (ULTA) Stock Rocketing Higher Today
The Detroit Lions (10-1) will play their annual Thanksgiving Day game on Thursday against NFC North foe, the Chicago Bears (4-7), at Ford Field. The Lions are flying high, winners of nine consecutive games and off to their best start since the franchise began in 1934. They'll be going up against a Bears team that has been reeling losers of four straight, including two against Green Bay Packers and Minnesota Vikings. The Lions are a little banged up heading into the contest, as they'll be without punt returner/wide receiver Kalif Raymond, offensive lineman Taylor Decker and cornerback Carlton Davis II. Amon-Ra St. Brown and David Montgomery are also questionable to play, according to the team's final injury report on Wednesday. Related: Lions injury report: Davis, Decker, Raymond out vs. Bears Follow us on Facebook The Bears have the edge in the all-time series, as Detroit is 78-105-5 against Chicago. The Lions lost the most recent game in December of last year but had the past three straight before that. Here's a look at what to expect and keys to watch as the Lions go for their 11th win on Thursday in front of their home fans. Why I'm Confident Josh: Lions Offense You know an offense has been playing well when their “down” week still saw them amass 390 yards and put up 24 points. That’s how good Detroit’s group has been, and they’ll match up with a Bears defense that has allowed 24.5 points per game over the past four weeks, ranking in the bottom-half of the league. Tommy: Teams of Two Tales The Lions are having an historic season for all the good reasons and it's a matchup against a team that is on the opposite side of that. While the Bears have been able to keep games close the past two weeks against NFC North opponents, the Lions will be their toughest challenge and Detroit should have all the confidence in the world heading into the contest. Why I'm Concerned Josh: Bears QB Caleb Williams For most of this season, Caleb Williams and Chicago’s offense have looked lost against any decent team. However, since the Bears changed offensive coordinators, there’s been a noticeable shift. Williams has had two of his best games, looked much more comfortable, has made some incredible throws and is effectively using his legs to extend plays and scramble for yards. Earlier in the year, this might’ve been a cakewalk for Detroit’s defense but it’ll be a test on Thursday. Tommy: Division Matchup It doesn't really matter at the end of the day what the records say, this is still an NFC North matchup and could be close just like Detroit's and Chicago's other two games this season against Minnesota and Green Bay. The Bears have showed promise the past two weeks in keeping the game close, so it'll be a proper test for the Lions, who as of late have been blowing out teams. Related: Lions' Kalif Raymond placed on IR, expected back for playoffs Key Matchup Josh: Lions Defensive Backs vs. Bears WR DJ Moore Since Thomas Brown took over play-calling for Chicago, Moore has gotten eight touches each game and racked up 186 total yards — his best two-game stretch of the season. Carlton Davis III has been fantastic for Detroit lately, but he’s banged up and may not be ready to go, which could force Terrion Arnold onto Moore. Whoever gets the assignment may need some help to prevent Moore from making an impact. Tommy: Bears WR Keenan Allen vs. Lions Defense Allen has seen the ball more from Caleb Williams, especially when DJ Moore is covered most of the game. The wide receiver hauled in nine catches for 86 yards and a touchdown against the Vikings last week, his best performance by far. He also torched the Lions defense last year with the Los Angeles Chargers, snagging 11 catches for 175 yards and two touchdowns. The Lions are without Davis II and have inexperience at the cornerback position with Terrion Arnold. Look for the Bears to continue feeding the former All-Pro on Thursday. All Eyes On Josh: Detroit's Defense Remarkably, the Lions are the only defense in the NFL to not yet allow multiple passing touchdowns in a game this season. With Chicago playing better and Detroit possibly down its top corner in Carlton Davis III, this will be a tough matchup for the Lions. Can they keep that streak alive and end the Thanksgiving losing streak? Tommy: Lions RB David Montgomery Just like Bears running back D'Andre Swift is facing his former team on Thursday, Montgomery will be doing the same, if he plays. As of Wednesday's final injury report, the running back is ruled as questionable with a shoulder injury he suffered against the Indianapolis Colts on Sunday. Chicago has allowed over 100 yards to a rusher. in eight of 11 games this season, and will have their hands full with Montgomery and Jahmyr Gibbs. Prediction Josh: 38-24 Lions Detroit leads the league in points per game at 32.7 but that jumps to 37.6 in home games — also best in the NFL. The Bears, meanwhile, average just 13.3 points per road game, the fewest in the league. Again, Chicago has looked much better the past two weeks and will be tough, but the Lions’ losing streak on Thanksgiving finally comes to an end. Tommy: 34-27 Lions Look, it's easy to say this will be a blowout. However, the Bears could very well keep this a close game throughout and possibly have a chance to win it if some things bounce their way. In 11 games this year, Chicago has played in seven one-possession games. Look for an eighth but Detroit comes out on top. Season Records Junfu Han / USA TODAY NETWORK via Imagn Images
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Dec. 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights , underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases . This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care—particularly delays in screenings, diagnoses, and treatments—have likely exacerbated the progression of advanced disease, diminished survival rates, and complicated long-term data analysis. Still, the oncology field continues to push forward with promising developments emerging from key innovators like O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cardiff Oncology, Inc. (NASDAQ: CRDF), Personalis, Inc. (NASDAQ: PSNL), Tempus AI, Inc. (NASDAQ: TEM), and Checkpoint Therapeutics, Inc. (NASDAQ: CKPT). The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031 —a clear indicator of oncology's rapid growth and critical importance. Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers, which were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025 . "We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer," said Tom Heineman , M.D., Ph.D., Chief Medical Officer of Oncolytics . "Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer. This offers the promise of delaying disease progression and improving survival in patients with these devasting diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients." Oncolytics will present two key data sets from the GOBLET study, with preliminary safety and tumor response results for the relapsed anal carcinoma cohort treated with pelareorep and atezolizumab presented in Poster Session C on January 25, 2025 , from 7:00 to 7:55 a.m. PT . Additionally, results from the safety run-in phase for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, with and without atezolizumab will be presented in Poster Session B on January 24, 2025 , from 11:30 a.m. to 1:00 p.m. PT . Both abstracts will be available on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025 . CONTINUED... Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). Efficacy and safety data are for all evaluable patients as of a November 26, 2024 , data cut-off date, and all efficacy data are determined by a blinded, independent central review (BICR) of each patient's tumor scan. "We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial," said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology . "Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses." Personalis, Inc. (NASDAQ: PSNL), a developer of advanced cancer genomic tests and analytics, and Tempus AI, Inc. (NASDAQ: TEM), an AI-powered healthcare technology company, recently announced they've expanded their commercial relationship. Both companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. "While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus' integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products," said Chris Hall , CEO of Personalis . "We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity." Under this expanded relationship, Tempus will be enabled to offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers who wish to bundle MRD testing with other Tempus offerings in a given study. Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), a commercial-stage immunotherapy and targeted oncology company focused on novel treatments for patients with solid tumor cancers, recently announced that the FDA approved its UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. "[This] FDA approval of UNLOXCYT – the first marketing approval for our company – is a significant milestone both for Checkpoint and for patients with advanced cSCC," said James Oliviero , President and CEO of Checkpoin t. "This approval marks Checkpoint's transformation to a commercial-stage company, with the opportunity to compete in a U.S. market estimated to exceed $1 billion annually, where we believe UNLOXCYT offers a differentiated treatment option versus available therapies by binding to PD-L1, rather than programmed death receptor-1 (PD-1), to release the inhibitory effects of PD-L1 on the anti-tumor immune response. Additionally, UNLOXCYT has demonstrated the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), another potential differentiating feature of the drug compared to existing marketed therapies for patients with cSCC." Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content: https://www.prnewswire.com/news-releases/oncology-advancements-accelerate-amid-rising-early-onset-cancer-diagnoses-302337555.html SOURCE USA News GroupDonegal Group Inc sees $271,376 in stock purchases by major shareholder
Stock market today: Wall Street gains ground as it heads for a winning weekIs the NORAD Santa tracker safe from a government shutdown?Stock market today: Wall Street rises toward more records